NAMS
Newamsterdam Pharma Co N.v. Health Care Pharmaceutical Preparations Russell 3000
$20.06Close
$2.3BMarket cap
$19.53 – $41.4552-week range
Nov 4, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 7 · weaker than 93% of stocks over 12 months
- Far from its high 52% below its 52-week high
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
52%
1wk
up 1.8%
price change
1mo
down 17.5%
price change
12-month return
down 48%
market up 11% ·
its own down 55%
F-score
—
— Not assessed
Altman Z
14.63
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.4×
price / book
Earnings yield
down 12.5%
EBIT / enterprise value
Cheaper than
22%
of the market · expensive
Revenue growth
down 51%
year on year
EPS growth
—
latest quarter
Sales growth
down 81%
latest quarter · -83 pts
ROE
down 28%
return on equity
Free cash margin
down 658%
-$148.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.1%
$1.22 a day · 2×ATR $17.62
RS
7 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.99
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 5.9% over the year, from 108m to 114m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 50.6% over the year, from $45.6M to $22.5M.
Last reported
Aug 5, 2026
Last shock
Sep 9, 2026-11% in one session2.1× volumeno filing matched-12% since
Financials
- Net -902%
- Free cash -658%
- Cash
- Long-term debt
| FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|
| Revenue | — | $102.7M | $14.1M | $45.6M | $22.5M |
| Operating income | -$35.0M | -$3.6M | -$183.0M | -$176.3M | -$225.7M |
| Net income | -$41.8M | -$22.6M | -$177.0M | -$242.0M | -$203.0M |
| Net margin | — | -22% | -1256% | -531% | -902% |
| Earnings per share | -$3.81 | -$1.19 | -$2.15 | -$2.56 | -$1.71 |
| Free cash flow | -$29.5M | $10.4M | -$141.2M | -$159.2M | -$148.0M |
| Free cash margin | — | 10% | -1002% | -349% | -658% |
| Cash | — | — | $340.4M | $771.7M | $490.0M |
| Shareholders' equity | -$113.8M | $430.1M | $288.4M | $757.5M | $683.4M |
| Shares outstanding | — | 81.56m | 82.47m | 108.06m | 114.40m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 18, 2026 | Annual ↗ | Dec 31, 2025 | 49d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Aug 7, 2023 | Interim ↗ | — | 0d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 29, 2026 | Other events ↗ |
| Sep 21, 2026 | Other events ↗ |
| Aug 14, 2026 | Director or officer change ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 24, 2026 | Other events ↗ |
| Jul 22, 2026 | Director or officer change ↗ |
| Jun 3, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 24, 2026 | Director or officer change ↗ |
| Mar 2, 2026 | Regulation FD ↗ |
| Feb 18, 2026 | Results ↗ |
| Jan 9, 2026 | Results · Regulation FD ↗ |